Email this article 
Post a Comment Efficiency of Transarterial Chemoembolization with Drug-Eluting Microspheres in the Treatment of Metastatic and Primary Liver Tumors
- Authors: Zvezdkina E.A.1, Kedrova A.G.2,3,4, Lebedev D.P.2, Krasilnikov S.E.4, Greyan T.A.2,3, Panchenkov D.N.1,2,5, Stepanova Y.A.5,6
-
Affiliations:
- The Skobelkin Research and Practical Centre for Laser Medicine
- Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies
- Academy of Postgraduate Education — Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies
- E. Meshalkin National Medical Research Center
- Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
- A.V. Vishnevsky National Medical Research Center of Surgery
- Issue: Vol 14, No 3 (2023)
- Pages: 27-35
- Section: Original Study Articles
- URL: https://journals.rcsi.science/clinpractice/article/view/253932
- DOI: https://doi.org/10.17816/clinpract562713
- ID: 253932
Cite item
Full Text
Abstract
Background: Transarterial chemoembolization (TACE) is coming into use in the treatment of liver tumors, with drug-eluting microspheres as one of the technique variations. However, at the moment there are no systematic studies that would answer the questions: what is the role of the method in the treatment regimen for patients with primary and metastatic liver tumor and at what stage should it be used? Aim: to evaluate the effectiveness of transarterial chemoembolization with drug-eluting microspheres for the treatment of metastatic and primary malignant liver tumors at different stages of the disease. Methods: We performed а retrospective observational uncontrolled study of 65 patients with liver metastases (Group 1), and 10 patients with primary malignant liver tumors (Group 2), who underwent 102 operations of transarterial chemoembolization with drug-eluting microspheres. To plan transarterial chemoembolization and evaluate its effectiveness, computed tomography and magnetic resonance imaging were used every 8–9 weeks during the treatment. Results: After two transarterial chemoembolization controls, Group 1 included 51 responders (79%) and 14 non-responders (21%). Among the responders by the 16th week there was a decrease in the volume of the tumor mass in the liver from 12.4 [4.7; 24.6] to 5.2 cm3 [2; 15.5] for colorectal cancer, from 26 [18; 35] to 19 cm3 [13; 25] for neuroendocrine cancer, from 12 [4; 20] to 4 cm3 [0.6; 9] for adenocarcinomas of different localizations. There was no progression in Group 2, while, by week 16, there was a decrease in the tumor volume from 142 [51; 206] to 68 cm3 [23; 185] for hepatocellular carcinoma, from 465 [330; 600] to 187 cm3 [137;237] for intrahepatic cholangiocarcinoma. With repeated transarterial chemoembolization, a decrease in the volume of the tumor mass was also noted, while the time without progression decreased from 303 [170; 369] to 180 [105; 225] days in Group 1, from 266 [200; 367] to 120 [62; 215] days in Group 2. Conclusions: Transarterial chemoembolization with drug-eluting microspheres is an effective treatment for primary and metastatic liver tumors. It should be considered as a palliative therapy, which allows achieving a good antitumor response at different stages of cancer.
Full Text
##article.viewOnOriginalSite##About the authors
Elena A. Zvezdkina
The Skobelkin Research and Practical Centre for Laser Medicine
Author for correspondence.
Email: zvezdkina@yandex.ru
ORCID iD: 0000-0002-0277-9455
SPIN-code: 8428-4518
MD, PhD, Research Associate
Russian Federation, MoscowAnna G. Kedrova
Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies; Academy of Postgraduate Education — Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies; E. Meshalkin National Medical Research Center
Email: kedrova.anna@gmail.com
ORCID iD: 0000-0003-1031-9376
SPIN-code: 3184-9760
MD, PhD, Dr. Sci. (Med.), Professor
Russian Federation, Moscow; Moscow; NovosibirskDmitry P. Lebedev
Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies
Email: lebedevdp@gmail.com
ORCID iD: 0000-0003-1551-3127
SPIN-code: 4770-5722
Russian Federation, Moscow
Sergey E. Krasilnikov
E. Meshalkin National Medical Research Center
Email: krasilnikov_s@meshalkin.ru
Scopus Author ID: 24461871200
Russian Federation, Novosibirsk
Tatevic A. Greyan
Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies; Academy of Postgraduate Education — Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies
Email: tatev111@gmail.com
ORCID iD: 0000-0003-4118-3002
SPIN-code: 6952-4709
Russian Federation, Moscow; Moscow
Dmitry N. Panchenkov
The Skobelkin Research and Practical Centre for Laser Medicine; Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies; Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
Email: dnpanchenkov@mail.ru
ORCID iD: 0000-0001-8539-4392
SPIN-code: 4316-4651
Russian Federation, Moscow; Moscow; Moscow
Yulia A. Stepanova
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov; A.V. Vishnevsky National Medical Research Center of Surgery
Email: stepanovaua@mail.ru
ORCID iD: 0000-0002-2348-4963
SPIN-code: 1288-6141
Russian Federation, Moscow; Moscow
References
- Долгушин Б.И., Косырев В.Ю. Радиочастотная термоаблация опухолей / под ред. М.И. Давыдова. Москва: Практическая медицина, 2015. 192 с. [Dolgushin BI, Kosyrev VYu. Radiofrequency thermal ablation of tumors. Ed. by M.I. Davydov. Moscow: Practical Medicine; 2015. 192 p. (In Russ).]
- Yoshino T, Cervantes A, Bando H, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer. ESMO Open. 2023;8(3):101558. doi: 10.1016/j.esmoop.2023.101558
- Рак печени (гепатоцеллюлярный). Клинические рекомендации. Ассоциация онкологов России, Междисциплинарное общество специалистов по опухолям печени, Общероссийская общественная организация «Российское общество клинической онкологии», Общероссийская общественная организация содействия развитию лучевой диагностики и терапии «Российское общество рентгенологов и радиологов», 2022. [Liver cancer (hepatocellular). Clinical recommendations. Association of Oncologists of Russia, Interdisciplinary Society of Specialists in Liver Tumors, All-Russian Public Organization «Russian Society of Clinical Oncology», All-Russian Public Organization for the Promotion of Radiation Diagnostics and Therapy «Russian Society of Radiologists and Radiologists»; 2022. (In Russ).]
- Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(4):238–255. doi: 10.1093/annonc/mdy
- Lucatelli P, Burrel M, Guiu B, et al. CIRSE standards of practice on hepatic transarterial chemoembolisation. Cardiovasc Intervent Radiol. 2021;44:1851–1867. doi: 10.1007/s00270-021-02968-1
- Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422. doi: 10.1093/annonc/mdw235
- Лаптева М.Г., Сергеева О.Н., Шориков М.А., и др. МРТ-оценка эффективности трансартериальной химиоэмболизации печени у пациентов с метастазами нейроэндокринных опухолей // Онкологический журнал. 2019. Т. 2, № 3. С. 21–30. [Lapteva MG, Sergeeva ON, Sharikov MA, et al. MRI-evaluation of the effectiveness of transarterial chemoembolization of the liver in patients with neuroendocrine tumor metastases. Oncological J. 2019;2(3):21–30. (In Russ).]
- Schicho A, Pereira PL, Pützler M, et al. Degradable starch microspheres transcatheter arterial chemoembolization (DSM-TACE) in intrahepatic cholangiocellular carcinoma (ICC): Results from a National multi-center study on safety and efficacy. Med Sci Monit. 2017;23:796–800. doi: 10.12659/msm.902901
- Vogl TJ, Marko C, Langenbach MC, Naguib N. Transarterial chemoembolization of colorectal cancer liver metastasis: Improved tumor response by DSM-TACE versus conventional TACE, a prospective, randomized, single-center trial. Eur Radiol. 2021;31(4):2242–2251. doi: 10.1007/s00330-020-07253-2
- Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157–176. doi: 10.1159/000335597
- Fjallskog ML, Janson ET, Falkmer UG, et al. Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors. Neuroendocrinology. 2008;88:53–58. doi: 10.1159/000117575
- Wang M, Zhang J, Ji S, et al. Transarterial chemoembolisation for breast cancer with liver metastasis: A systematic review. Breast. 2017;36:25–30. doi: 10.1016/j.breast.2017.09.001
- De Baere T, Plotkin S, Yu R, et al. An in vitro evaluation of four types of drug-eluting microspheres loaded with doxorubicin. J Vasc Interv Radiol. 2016;27(9):1425–1431. doi: 10.1016/j.jvir.2016.05.015
- Kennoki N, Saguchi T, Sano T, et al. Long-term histopathologic follow-up of a spherical embolic agent; observation of the transvascular migration of HepaSphere TM. BJR Case Rep. 2019;5(1):20180066. doi: 10.1259/bjrcr.20180066
- Котив Б.Н., Дзидзава И.И., Алентьев С.А., Смородский А.В. Комплексное лечение при гепатоцеллюлярном раке на ранней (BCLC-A) и промежуточной (BCLC-В) стадии // Анналы хирургической гепатологии. 2020. Т. 25, № 2. С. 55–66. [Kotiv BN, Dzidzava II, Alentyev SA, Smorodsky AV. Complex treatment for hepatocellular cancer at an early (BCLCA) and intermediate (BCLC-B) stage. Ann Surg Hepatol. 2020;25(2): 55–66. (In Russ).] doi: 10.16931/1995-5464.2020255-66
Supplementary files
